AMEX · THNR
Amplify Weight Loss Drug & Treatment ETF
$25.95+$0.59 (+2.35%)
Amplify Weight Loss Drug & Treatment ETF’s quoted price sits in the upper half of its reported 52-week range, 7.12% below the high.
Loading market information…
NASDAQ · MCHS · USD
Stock price, dividends
Quote as of Oct 30, 2026, 08:00 PM UTC. Cached market data; not a live quote.
One-year closing-price history · USD. Historical prices are not a forecast.
Matthews China Discovery Active ETF MCHS’s quoted price sits in the lower half of its reported 52-week range, 37.32% below the high.
52-week range
Go beyond this overview with deeper company research in PortfolioX. Explore more in the app
THE INCOME SIDE
Historical amounts are adjusted for stock splits. Understand ex-dividend and payment dates →
Completed calendar years and any current-year payments shown separately. Current-year totals are incomplete until all payments are made.
THE COMPANY BEHIND THE TICKER
Under typical circumstances, the Matthews China Discovery Active ETF endeavors to achieve its investment objective by dedicating a minimum of 65% of its net assets, which includes capital acquired through borrowing for investment, to the equity securities (both common and preferred stock) of smaller companies. Additionally, at least 80% of the fund's total net assets, again accounting for any borrowed funds, will be invested in the common and preferred shares of firms based in China. This fund maintains a non-diversified portfolio.
Latest available per-share figures in USD. The payout ratio compares dividends with earnings.
About this data · PortfolioX market data, also available in the mobile app. Prices are displayed in the listing currency; dividend amounts use the currency shown in that section. Data availability and update times vary.
Page generated Nov 1, 2026, 09:24 AM UTC. Quotes retain their own timestamp above. Missing values appear as a dash. This page is for information only, not personalized investment advice.
KEEP COMPARING
$25.95+$0.59 (+2.35%)
Amplify Weight Loss Drug & Treatment ETF’s quoted price sits in the upper half of its reported 52-week range, 7.12% below the high.
$13.83+$0.07 (+0.54%)
Genter Capital Dividend Income ETF’s quoted price sits in the upper half of its reported 52-week range, 0.59% below the high.
$11.93+$0.38 (+3.26%)
Polen Capital Emerging Markets ex China Growth ETF’s quoted price sits in the upper half of its reported 52-week range, 7.82% below the high.
$30.22-$0.01 (-0.02%)
USCF ETF Trust - USCF Sustainable Commodity Strategy Fund’s quoted price sits in the upper half of its reported 52-week range, 5.73% below the high.
$30.61+$0.21 (+0.67%)
Westwood LBRTY Global Equity ETF’s quoted price sits in the upper half of its reported 52-week range, 2.27% below the high.
$36.54+$0.12 (+0.34%)
AdvisorShares Hotel ETF’s quoted price sits in the upper half of its reported 52-week range, 4.62% below the high.
$27.20+$0.18 (+0.67%)
AdvisorShares Restaurant ETF’s quoted price sits in the lower half of its reported 52-week range, 13.97% below the high.
$26.23$0.00 (0.0%)
KraneShares 100% KWEB Defined Outcome January 2027 ETF’s quoted price sits in the lower half of its reported 52-week range, 15.32% below the high.
